GeneDx Holdings Corp. - Class A Common Stock (WGS)
91.78
+6.87 (8.09%)
NASDAQ · Last Trade: Jul 29th, 6:52 PM EDT
Detailed Quote
Previous Close
84.91
Open
105.31
Bid
91.90
Ask
93.55
Day's Range
89.00 - 106.68
52 Week Range
25.32 - 117.75
Volume
3,322,159
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
716,703
Chart
About GeneDx Holdings Corp. - Class A Common Stock (WGS)
GeneDx Holdings Corp. is a genomics company that specializes in providing genetic testing services to aid in the diagnosis and treatment of various genetic disorders. By leveraging advanced genomic technologies and bioinformatics, the company aims to deliver accurate and comprehensive genetic information that helps clinicians make informed decisions about patient care. GeneDx focuses on enhancing the understanding of rare and hereditary diseases, facilitating personalized medicine, and improving patient outcomes through insightful genomic data services. Read More
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.
GeneDx Holdings Corp (WGS) shows strong earnings & revenue growth, positive analyst revisions, and solid technicals, making it a high-growth momentum stock with breakout potential.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS), GeneDx (WGS), Lineage (LINE), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CTO Realty (CTO), GeneDx (WGS), Quantum (QMCO), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS), GeneDx (WGS), Lineage (LINE), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time.
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children’s supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical pediatric inpatients. The study assessed the impact of using rES/rGS as a first-tier test for children receiving genetic consults in non-critical care settings. The researchers examined diagnostic rates before and after a new policy allowing rES/rGS as a first-tier test was implemented. An analysis published in The Journal of Pediatrics showed that rapid genome testing dropped the average time to a precise genetic diagnosis from almost ten months to less than two weeks.
